This report provides a snapshot of approved drugs and drug pipelines for the treatment of AML. This report includes AML background, an overview of available AML treatments, and key clinical trial data and comments.

Given the advanced age of the average AML patient, we believe that treatments for AML will need to have improved safety profiles. Many AML patients are unable to tolerate cytotoxic induction therapy, and targeted treatments have the potential to effect clinical benefit with reduced induction mortality rates. We caution, however, that targeted treatments can have harsh side effect profiles as well – particularly if they target the cell cycle or have effects on off-target proteins or on cells involved with normal hematopoiesis.

We believe that the future of AML treatment will strongly depend on basic research elucidating detailed mechanistic information on targeted agents in AML cell lines, AML primary cells, and in patients. AML and associated myeloid disorders are heterogeneous entities, and patients with different chromosomal and molecular aberrations may have sharply different responses to targeted treatments.

This report accompanies our other AML content planned for April 2015. We also published an interview with a KOL (pediatric AML/ALL specialist), an interview with an MDS/AML specialist, and we plan to publish a report on AML Diagnostics, in collaboration with MedDeviceTracker. For more information on MedDeviceTracker's diagnostics coverage, please visit the MedDeviceTracker website or contact your BioMedTracker sales representative.

For the full report, please download the PDF version at the top of this page. A list of selected AML drug catalysts is provided as a supplement (click on the file icon below the report PDF).

For our disclosures, please read the BioMedTracker Research Standards.